Skip to content

Characterisation of MNEsic Involvement in Patients With Obesity.

Characterisation of MNEsic Involvement in Patients With Obesity.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07796932
Acronym
MNEMOB
Enrollment
150
Registered
2026-09-01
Start date
2027-01-01
Completion date
2030-02-01
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity (Disorder)

Keywords

neurological inflammation, Obesity, CANTAB

Brief summary

The aim of the study is therefore to characterise memory impairment in a middle-aged population with obesity and to clarify the role of inflammation in obesity-related memory impairment. The hypothesise that, as in an elderly population, neurological and memory impairment in a population of middle-aged obese individuals is heterogeneous, with varying levels of memory impairment characterised by neuropsychological test results. This heterogeneity in neuropsychological tests may be linked to markers of inflammation and brain imaging biomarkers identified previously in the litterature.

Interventions

OTHERRMI and Questionnaires

Magnetic resonance imaging (MRI) will collect anatomical information (3D T1 weighted images) to compute the volumes of the hypothalamus, hippocampus and the other brain parcels. Executive functions using the CANTAB tests and validated questionnaires will be performed.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients suffering from obesity with a BMI between 30 and 45 kg/m² * Patients aged between 30 and 50 receiving educational care during the week at the CSO (Endocrinology, Diabetology and Nutrition Department) of the Bordeaux University Hospital. * Right-handed patients * Persons affiliated with or beneficiaries of a social security scheme. * Free, informed and express consent

Exclusion criteria

* Patients currently undergoing treatment with neuroleptics or who have stopped treatment within the last 3 months. * Pregnant or breastfeeding patients * Known current or past neurological disease * Proven depressive syndrome treated * Patients with type 1 or type 2 diabetes * Uncontrolled dysthyroidism * MMS\< 25 * Patients with proven genetic obesity * Contraindication to MRI * Chronic use of NSAIDs or corticosteroids * Loss of 5% of body weight in the 3 months prior to the study * Acute infection * Persons deprived of their liberty by judicial or administrative decision * Adults subject to legal protection measures (guardianship, curatorship, judicial protection)

Design outcomes

Primary

MeasureTime frameDescription
Memory function characteristic37 months after inclusion dayThe main objective is to characterise memory function in a population of middle-aged individuals suffering from obesity using the CANTAB Paired Associates Learning (PAL) test.

Contacts

CONTACTBlandine GATTA-CHERIFI, Pr
blandine.gatta-cherifi@chu-bordeaux.fr05 24 54 93 41
STUDY_DIRECTORDaniela COTA, Pr

INSERM u1215

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026